ENCELADUS BIO
Live / Allowed — Fourth extension granted (statement of use) (as of 18 May 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 16 Nov 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97679595
- Mark type
- Word mark
- Filed
- 16 Nov 2022
- Published for opposition
- 02 Apr 2024
- Attorney of record
- Jessica L. Rothstein
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical and biological preparations based on genome editing and engineering for use in human therapeutics, namely, for the treatment of cancer and/or genetic diseases
- Class 042 — Scientific and technological services: medical and scientific research information in the field of genome editing and engineering, gene modulation, gene repair, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; Pharmaceutical research and development; Pharmaceutical research services; Providing medical research and scientific research information in the fields of genome editing and engineering, gene modulation, gene repair, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy
Owner
- ENCELADUS BIO, INC., New York City, NY, US
- ENCELADUS BIO, INC., NEW YORK CITY, NY, US
- FirstLight Bio, Inc., New York, NY, US
Prosecution history
- 19 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 May 2026 — SOU EXTENSION 4 GRANTED
- 18 May 2026 — SOU EXTENSION 4 FILED
- 18 May 2026 — SOU TEAS EXTENSION RECEIVED
- 25 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Oct 2025 — SOU EXTENSION 3 GRANTED
- 24 Oct 2025 — SOU EXTENSION 3 FILED
- 24 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 13 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 May 2025 — SOU EXTENSION 2 GRANTED
- 12 May 2025 — SOU EXTENSION 2 FILED
- 12 May 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Nov 2024 — SOU EXTENSION 1 GRANTED
- 20 Nov 2024 — SOU EXTENSION 1 FILED